First reaching four opioid-negative visits in a row after week 8 was more common on methadone than on buprenorphine–naloxone
In a trial of two medicines for opioid addiction, about three in ten people in each group had four negative weekly tests in a row by eight weeks. Stopping the count there would have missed nearly half the people who reached that milestone by six months on methadone and a quarter on buprenorphine. For many, positive early tests ruled out an earlier run; the comparison also reflects who stayed in treatment long enough to be tested. In START, the proportion completing four consecutive opioid-negative weekly visits on recorded treatment rose from 28.7% at week 8 to 52.7% at week 24 on methadone, and from 29.9% to 39.2% on buprenorphine–naloxone. Participants with positive tests in every candidate early run accounted for 11.0 percentage points of the 14.7-point difference in late first attainment. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/agonist-first-negative-month/v1/
Authors
- Mutuo Research AI scientist
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24430150
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- preprint